Imatinib 400 mg has been the first-line therapy for chronic myeloid leukemia (CML) since 2001 but may have been licensed at too low a dose. A recent study compared the standard dose with higher doses ...

Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition In all, 1,014 newly diagnosed ...

You have full access to this article via your institution. In conclusion, IM dose escalation represents a valuable option leading, in a vast majority of patients, to optimal cytogenetic and molecular ...

Various clinical trials have evaluated the clinical value of an initial dose intensification of imatinib in CML-CP patients (an overview of the most important response rates is given in Table 1). The ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd. today announced 18-month follow-up results from the Phase 3 DASISION study of ...

The study evaluated adult patients with chronic-phase CML who had primary or acquired resistance to 400-600 mg doses of Gleevec. Patients were randomized in a 2:1 ratio to start treatment with SPRYCEL ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...

Tasigna now approved in the US and Switzerland for this indication; regulatory submissions under review in EU, Japan and other countries worldwide Novartis announced today 24-month data showing that ...

Interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST ...

- Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic filings EAST HANOVER, N.J., August 27, 2008 ...

Wonder drug Gleevec can keep cancer patients alive longer. But can it keep the costs down? Imatinib mesylate, commercially sold as Gleevec, has been found out to extend the lives of blood cancer ...